Bharat Immunologicals & Biologicals Corporation Limited (BOM:524663)
India
· Delayed Price · Currency is INR 22.70
-0.21 (-0.92%)
At close: May 2, 2025
BOM:524663 Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2014 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '23 Sep 30, 2023 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | Mar '19 Mar 31, 2019 | 2014 - 2018 |
| Net Income | - | -166.39 | -87.54 | -181.13 | -102.11 | -57.93 | Upgrade
|
| Depreciation & Amortization | - | 2 | 2.13 | 2.37 | 2.37 | 2.76 | Upgrade
|
| Other Operating Activities | - | 4.95 | 41.27 | 296.94 | -1.52 | -18.19 | Upgrade
|
| Change in Accounts Receivable | - | -127.43 | -11.23 | 176.03 | 553.58 | -570.28 | Upgrade
|
| Change in Inventory | - | 348.28 | -227.59 | 382.28 | -372.8 | -127.18 | Upgrade
|
| Change in Accounts Payable | - | 1.62 | -139.24 | -287.38 | -6.53 | 437.66 | Upgrade
|
| Change in Unearned Revenue | - | - | - | - | - | -13.84 | Upgrade
|
| Change in Other Net Operating Assets | - | 45.9 | 1.05 | -271.35 | 267.8 | 26.04 | Upgrade
|
| Operating Cash Flow | - | 108.92 | -421.15 | 117.77 | 340.79 | -320.96 | Upgrade
|
| Operating Cash Flow Growth | - | - | - | -65.44% | - | - | Upgrade
|
| Capital Expenditures | - | - | - | - | -0.01 | -0.25 | Upgrade
|
| Other Investing Activities | - | 4.62 | 5.31 | 6.69 | 9.13 | 7.23 | Upgrade
|
| Investing Cash Flow | - | 4.62 | 5.31 | 6.69 | 9.12 | 6.98 | Upgrade
|
| Short-Term Debt Issued | - | - | 505.92 | 242.55 | - | 322.22 | Upgrade
|
| Total Debt Issued | - | - | 505.92 | 242.55 | - | 322.22 | Upgrade
|
| Short-Term Debt Repaid | - | -76.6 | - | - | -291.84 | - | Upgrade
|
| Total Debt Repaid | - | -76.6 | - | - | -291.84 | - | Upgrade
|
| Net Debt Issued (Repaid) | - | -76.6 | 505.92 | 242.55 | -291.84 | 322.22 | Upgrade
|
| Other Financing Activities | - | -70.52 | -55.92 | -364.58 | -52.31 | -15.15 | Upgrade
|
| Financing Cash Flow | - | -147.12 | 450 | -122.03 | -344.14 | 307.07 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | - | - | - | - | - | -1 | Upgrade
|
| Net Cash Flow | - | -33.57 | 34.16 | 2.43 | 5.77 | -7.9 | Upgrade
|
| Free Cash Flow | - | 108.92 | -421.15 | 117.77 | 340.79 | -321.21 | Upgrade
|
| Free Cash Flow Growth | - | - | - | -65.44% | - | - | Upgrade
|
| Free Cash Flow Margin | - | 24.42% | -53.73% | 13.80% | 50.99% | -38.40% | Upgrade
|
| Free Cash Flow Per Share | - | 2.52 | -9.75 | 2.73 | 7.89 | -7.44 | Upgrade
|
| Cash Interest Paid | - | 70.49 | 55.92 | 47.77 | 47.42 | 20.04 | Upgrade
|
| Levered Free Cash Flow | - | 125.24 | -476.84 | -172.27 | 367.5 | -354.34 | Upgrade
|
| Unlevered Free Cash Flow | - | 168.76 | -444.91 | -145 | 392.89 | -345.23 | Upgrade
|
| Change in Net Working Capital | -275.2 | -267.08 | 414.77 | 15.64 | -456.08 | 289.24 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.